Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes

JW Pharmaceutical1,538 enrolled

Overview

A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® according to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients

A Multi-center, Open-label, Observational Study

Study Type

OBSERVATIONAL

Enrollment

1,538

Conditions

Hypercholesterolemia

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women aged ≥19 years * Diagnosed with hypercholesterolemia * LDL-C level meets cardiovascular/cerebrovascular risk group classification * Willing to participate for 12 months * Provided written informed consent Exclusion Criteria: \- Contraindications to Livalozet®

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

Percent change from baseline in LDL-C level at Week 24

Time frame: From enrollment to the end of treatment at 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.